Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.
Financial terms of the projects weren't disclosed.
The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.
Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.
The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。